Exom Group is proud to announce that the results of CARAVAGGIO, a practice-changing study, have been presented at the ACC Virtual 2020 and published on the NEJM on March 29th, 2020. DOI: 10.1056/NEJMoa1915103 The study involved 159 clinical sites distributed in 9...
The clinical trials sector is going through a challenging and delicate phase, that could lead to a slowdown in drug development in general. In an attempt to limit damage, safeguard the validity of the data and protect the health of patients by guaranteeing their...
Even before the crisis hit, there had been a push towards the digitization of clinical research, but this epidemic brings with it a greater urgency. The implementation of digital technologies such as remote monitoring of patients and eSource for collecting and...
Global Health & Pharma Excellence AwardsAward Winner 2022
Exom is proud to announce that Global Health & Pharma has awarded us the 2022 Global Excellence Award as "Most innovative Full-Service CRO - 2022" for our pioneering, cutting-edge use of technology in clinical trials to support study stakeholders.